TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21355097

Group type: EXPERIMENTAL
Intervention: Romidepsin (depsipeptide or FK228), a histone deacetylase inhibitor
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study: 21355725

Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (Animas(®) 2020, Animas Corp.) for 16 weeks
Number of subjects: 54
Study: 21356058

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 9967

Group type: COMPARATOR
Intervention: Other gastrointestinal drugs (except PPIs)
Number of subjects: 9967
Study: 21356079

Group type: EXPERIMENTAL
Intervention: Canakinumab 2 mg/kg subcutaneously (s.c.) for patients with body weight ≤ 40 kg or 150 mg s.c. for patients with body weight > 40 kg.
Number of subjects: 7
Study: 21356124

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) 0.5 mg/kg normal body weight/day, injected subcutaneously for 14 days, followed by a break of one week, repeated to a maximum of nine times.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) treatment in 12 patients who completed all nine cycles.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) treatment in 20 patients.
Number of subjects: 20
Study: 21357363

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21357390

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 18
Study: 21357403

Group type: EXPERIMENTAL
Intervention: MMP-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MMP-3
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Immunostaining of MMP-1 and -3
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cultured conjunctival fibroblasts
Number of subjects: 8

Group type: COMPARATOR
Intervention: MMP-2 and TIMP-1 and -2
Number of subjects: 8

Group type: COMPARATOR
Intervention: MMP-9
Number of subjects: 8
Study: 21357404

Group type: EXPERIMENTAL
Intervention: MMC-treated off-flap
Number of subjects: 93

Group type: COMPARATOR
Intervention: MMC-treated on-flap
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-MMC treated on-flap
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-MMC treated off-flap
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: on-flap
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: off-flap
Number of subjects: 93
Study: 21358295

Group type: EXPERIMENTAL
Intervention: Capecitabine (1,250 mg/m² twice daily for 14 days, followed by 14 days of rest)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 51
Study: 21358414

Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation via percutaneous endovascular radiofrequency ablation
Number of subjects: 2
Study: 21358415

Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) at 1 year
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: UACR (urine albumin/creatinine ratio) at baseline
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon (left ventricular hypertrophy) at baseline
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: Cornell product (1 year)
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: UACR (1 year)
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: Presence of left ventricular hypertrophy by Cornell product (1 year) or UACR (1 year) at least 1 mmol/l
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: FRS (1 year) above the median baseline value of 20
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: SOD (subclinical organ damage) (1 year)
Number of subjects: 6460

Group type: EXPERIMENTAL
Intervention: Cornell product (1 year) and UACR (1 year)
Number of subjects: 6460
Study: 21359089

Group type: EXPERIMENTAL
Intervention: Caffeine consumption prior to polysomnography
Number of subjects: 958

Group type: COMPARATOR
Intervention: No caffeine consumption prior to polysomnography
Number of subjects: 958
Study: 21359193

Group type: EXPERIMENTAL
Intervention: Iodine deficiency (mean urinary iodine excretion, 49.8 µg/L)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal iodine levels (not explicitly mentioned in the abstract)
Number of subjects: 110
Study: 21359517

Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: QCA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IVUS
Number of subjects: 45

Group type: COMPARATOR
Intervention: IVUS-OCT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Videodensitometry-IVUS
Number of subjects: 45
Study: 21359953

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,000 mg/day and nab-paclitaxel 260 mg/m2 every 3 weeks for four cycles
Number of subjects: 30
Study: 21360250

Group type: EXPERIMENTAL
Intervention: Indocyanine green adsorbed to human serum albumin (ICG:HSA) at concentrations from 50 to 1000 μM, injected after patent blue.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard of care with (99m)Technetium-nanocolloid and patent blue.
Number of subjects: 24
Study: 21361910

Group type: EXPERIMENTAL
Intervention: Bovine milk powder extracts
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk powder
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Alpha-casein
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Beta-casein
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Milk-reactive IAA
Number of subjects: 53
Study: 21362702

Group type: EXPERIMENTAL
Intervention: Roche high-sensitive cTnT (hs-cTnT)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Siemens cTnI-Ultra
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Abbott-Architect cTnI
Number of subjects: 406

Group type: COMPARATOR
Intervention: Standard assay (Roche cTnT)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Sensitive cTn assays
Number of subjects: 406
Study: 21366812

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (1-year duration)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: G-allele of rs10830963
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1118
Study: 21367924

Group type: EXPERIMENTAL
Intervention: Direct water deprivation test (WDT) with copeptin measurement
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Direct water deprivation test (WDT) with AVP measurement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Indirect water deprivation test (WDT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Baseline copeptin values greater than 20 pmol/liter
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Baseline copeptin values below 2.6 pmol/liter
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Δ copeptin ratio (0800 to 1600 h) to serum sodium concentration at 1600 h
Number of subjects: 70
Study: 21367942

Group type: EXPERIMENTAL
Intervention: Serum potassium concentrations <4.0 mEq/L
Number of subjects: 12209

Group type: EXPERIMENTAL
Intervention: Serum potassium concentrations 4.0-4.4 mEq/L
Number of subjects: 12209

Group type: EXPERIMENTAL
Intervention: Serum potassium concentrations 4.5-4.9 mEq/L
Number of subjects: 12209
Study: 21368592

Group type: EXPERIMENTAL
Intervention: Protease inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21368772

Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 994
Study: 21369751

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 1133
Study: 21371308

Group type: EXPERIMENTAL
Intervention: Extracorporeal plasma treatment with a granulocyte bioreactor, treated twice within 72 hours for a mean of 342 ± 64 minutes/treatment with 1.41 ± 0.43 × 10E10 granulocytes from healthy donors.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extracorporeal plasma treatment with a granulocyte bioreactor
Number of subjects: 10
Study: 21372112

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO) 2500 orally every 2 weeks for 3 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Number of subjects: 5
Study: 21372155

Group type: EXPERIMENTAL
Intervention: Integrative prognostic risk score (IPRS)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: High-risk patients with related donors
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Intermediate-risk group patients with related donors
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Low-risk group patients
Number of subjects: 406
Study: 21372167

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 9
Study: 21372218

Group type: EXPERIMENTAL
Intervention: E7080 13 mg bid
Number of subjects: 27
Study: 21372302

Group type: EXPERIMENTAL
Intervention: 20 mg/day simvastatin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 40 mg/day simvastatin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin (48 hours after admission)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Early statin treatment
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Higher statin doses
Number of subjects: 125
Study: 21372613

Group type: EXPERIMENTAL
Intervention: Risk allele rs17782313 in males
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Risk allele rs17782313 in females
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Risk allele rs17782313
Number of subjects: 889

Group type: COMPARATOR
Intervention: Normal-weight and lean controls
Number of subjects: 889
Study: 21375584

Group type: EXPERIMENTAL
Intervention: SPINK-1/N34S mutation
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (without SPINK-1/N34S mutation)
Number of subjects: 239
Study: 21375763

Group type: EXPERIMENTAL
Intervention: CFS with migraine without aura (CFS+MO)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: CFS with migraine with aura (CFS+MA)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: CFS with tension headaches only
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: CFS with no headaches
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: CFS with co-morbid tension and migraine headaches
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: CFS+MA
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: CFS+MO
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 203

Group type: COMPARATOR
Intervention: HC
Number of subjects: 203
Study: 21376047

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Noninvasive tests for fibrosis
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Severe fibrosis diagnosis
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Liver stiffness and FibroTest values
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Liver stiffness
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: FibroTest results
Number of subjects: 1457
Study: 21376093

Group type: EXPERIMENTAL
Intervention: Exercise session
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sedentary session
Number of subjects: 14
Study: 21376417

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nateglinide and Acarbose
Number of subjects: 58
Study: 21377509

Group type: EXPERIMENTAL
Intervention: H6N1 influenza virus vaccine (10^7 TCID(50), 2 doses)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: H6N1 influenza virus vaccine (2 doses)
Number of subjects: 22
Study: 21377994

Group type: EXPERIMENTAL
Intervention: Romidepsin at a dosage of 13.3 mg/m(2)/day on days 1, 8, and 15 of each 28-day cycle (phase II component)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Romidepsin at a dosage of 17.7 mg/m(2)/d (phase I component)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Romidepsin at a dosage of 13.3 mg/m(2)/d (phase I component)
Number of subjects: 43
Study: 21378375

Group type: EXPERIMENTAL
Intervention: Inactivated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live attenuated vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21380781

Group type: EXPERIMENTAL
Intervention: Zoladex combined with CEF chemotherapy
Number of subjects: 119
Study: 21381158

Group type: EXPERIMENTAL
Intervention: Positive Edinburgh Postnatal Depression Scale (EPDS≥10) indicating postpartum depression risk
Number of subjects: 9339

Group type: EXPERIMENTAL
Intervention: Suicidal ideation (SI) as measured by item 10 of the EPDS
Number of subjects: 9339

Group type: EXPERIMENTAL
Intervention: Seasonality in postpartum depression risk
Number of subjects: 9339

Group type: EXPERIMENTAL
Intervention: Seasonality in suicidal ideation
Number of subjects: 9339
Study: 21381892

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 300 μg weekly
Number of subjects: 44
Study: 21382172

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (Clopidogrel and Aspirin)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no ST)
Number of subjects: 84
Study: 21383241

Group type: EXPERIMENTAL
Intervention: Tofacitinib (CP-690,550)
Number of subjects: 0
Study: 21383282

Group type: EXPERIMENTAL
Intervention: Elevated serum free light chains (FLC)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Abnormal κ:λ FLC ratio
Number of subjects: 295

Group type: COMPARATOR
Intervention: Normal serum free light chains (FLC)
Number of subjects: 295
Study: 21383285

Group type: EXPERIMENTAL
Intervention: ARQ 197 at 100 to 400 mg twice per day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ARQ 197
Number of subjects: 51
Study: 21383338

Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg)
Number of subjects: 18
Study: 21384515

Group type: EXPERIMENTAL
Intervention: Flush blood from liver grafts
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Catecholamines used to maintain mean arterial pressure
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IL-1β, IL-2, IL-8 levels in flush blood
Number of subjects: 17
Study: 21386092

Group type: EXPERIMENTAL
Intervention: 81 mg/od
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 81 mg/bid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 162 mg/bid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin dosing regimens
Number of subjects: 20
Study: 21386111

Group type: EXPERIMENTAL
Intervention: MRI protocol with a 32 item ordinal scale evaluating abnormalities in the basal ganglia and posterior fossa.
Number of subjects: 760
Study: 21386974

Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg per day)
Number of subjects: 29133
Study: 21386997

Group type: EXPERIMENTAL
Intervention: H5N1 globular domain HA1(1-330) and HA0(1-500) proteins
Number of subjects: 2

Group type: COMPARATOR
Intervention: H5N1 inactivated sub-virion vaccine
Number of subjects: 2
Study: 21387287

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21388308

Group type: EXPERIMENTAL
Intervention: Interstitial lung abnormalities present
Number of subjects: 2416
Study: 21388319

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hemodialysis
Number of subjects: 0
Study: 21388310

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg once daily
Number of subjects: 9016

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9016
Study: 21388447

Group type: EXPERIMENTAL
Intervention: Electrocardiographic signs (heart rate, cQT-interval, atrial fibrillation/flutter, left axis deviation, right and left bundle branch block)
Number of subjects: 5231
Study: 21389182

Group type: EXPERIMENTAL
Intervention: G/G genotype with low saturated fatty acid (SFA) concentrations (below the median)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: G/G genotype with high saturated fatty acid (SFA) concentrations (above the median)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Minor A allele (G/A and A/A) with high saturated fatty acid (SFA) concentrations
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: CAPN10 rs2953171 SNP
Number of subjects: 452
Study: 21391024

Group type: EXPERIMENTAL
Intervention: Clinician ratings of treatment improvement
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Blinded laboratory rater reports
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Parent and child pre-post reports of social anxiety symptoms
Number of subjects: 101
Study: 21391405

Group type: EXPERIMENTAL
Intervention: Typical caregivers (spouse, children)
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Atypical caregivers (in-law, sibling, nephew/niece, grandchild)
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Caregiving experience
Number of subjects: 1476
Study: 21393027

Group type: EXPERIMENTAL
Intervention: CT scans analyzed using the threshold technique (%<-950HU) and low attenuation cluster analysis
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: CT scans scored as showing regions of gas trapping
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: Visual estimates of emphysema
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: Computer analysis of low attenuation cluster size
Number of subjects: 1972
Study: 21393326

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells expanded using human serum
Number of subjects: 18
Study: 21393329

Group type: EXPERIMENTAL
Intervention: Deferasirox monotherapy (30-40 mg/kg/day) for 18 months
Number of subjects: 0
Study: 21393334

Group type: EXPERIMENTAL
Intervention: Early discharge after chemotherapy completion with close outpatient follow up
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inpatient control group
Number of subjects: 20
Study: 21393393

Group type: EXPERIMENTAL
Intervention: Self-paced walk (SPW) after rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-paced walk (SPW) before rehabilitation
Number of subjects: 50
Study: 21394036

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg alone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fimasartan 120 mg with Amlodipine 10 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg alone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Amlodipine 10 mg with Fimasartan 120 mg
Number of subjects: 34
Study: 21395631

Group type: EXPERIMENTAL
Intervention: Enteric-coated cysteamine (mean dose 15.2 mg/kg/day) for 24 weeks
Number of subjects: 13
Study: 21396639

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (without IBD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients with ulcerative pan-colitis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients with severe clinical disease
Number of subjects: 28
Study: 21396809

Group type: EXPERIMENTAL
Intervention: Continuous supplemental oxygen therapy
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Factors associated with oxygen use in non-hypoxemic patients
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Risk factors for hypoxemia
Number of subjects: 1060
Study: 21397456

Group type: EXPERIMENTAL
Intervention: Laser anterior capsulotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual continuous curvilinear capsulorhexis (CCC)
Number of subjects: 0
Study: 21398104

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) metered-dose inhaler (MDI) 100/10 μg with integrated dose counter, used twice daily for 4 weeks
Number of subjects: 233

Group type: COMPARATOR
Intervention: Counterstrip™, a manual counting method
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: MF/F MDI with integrated dose counter
Number of subjects: 233
Study: 21398284

Group type: EXPERIMENTAL
Intervention: Meibomian gland dysfunction (Md)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal donors (Mn)
Number of subjects: 0
Study: 21398296

Group type: EXPERIMENTAL
Intervention: Panobacumab (1.2 mg/kg, given every 72 h)
Number of subjects: 18
Study: 21398330

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 30
Study: 21398392

Group type: EXPERIMENTAL
Intervention: DNA vaccine encoding the protein premembrane and the E glycoproteins of the NY99 strain of WNV, administered in a 3-dose regimen.
Number of subjects: 30
Study: 21402043

Group type: EXPERIMENTAL
Intervention: Vaccination coverage for all vaccines part of the Expanded Program on Immunization (EPI)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: All recommended vaccines received
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Timely vaccination for measles vaccine
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Timely vaccination for Bacillus Calmette-Guérin (BCG) vaccine
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: All vaccines received within recommended time ranges
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation coverage
Number of subjects: 765
Study: 21403014

Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography (CTCA)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 169
Study: 21403127

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for CD20(+) patients
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for CD20(-) patients
Number of subjects: 157

Group type: COMPARATOR
Intervention: Comparison of relapse rates between CD20(+) and CD20(-) patients
Number of subjects: 157
Study: 21403139

Group type: EXPERIMENTAL
Intervention: 30-minute office blood pressure measurement (OBPM)
Number of subjects: 84